HistoIndex, an AI-driven digital pathology solutions for chronic liver disease, has announced a partnership with Houston Research Institute (HRI), a US-based research organisation specialising in hepatology and gastroenterology clinical trials, with a focus on metabolic liver disease.

The collaboration marks an important expansion of HistoIndex’s commercial partnerships with hepatology and gastroenterology medical centres across the United States and Europe. Through this alliance, HistoIndex will provide advanced diagnostic testing services to patients with Metabolic Dysfunction–associated Steatohepatitis (MASH), enabling more accurate disease assessment and improved clinical decision-making.

As part of the partnership, all four HRI medical centres Houston Research Institute Pasadena, Houston Research Institute Sugar Land, Houston Research Institute and Houston Research Institute Medical Centre will gain access to HistoIndex’s integrated diagnostic platform. The offering combines expert histopathological evaluation by experienced pathologists with advanced AI-based biopsy analysis.

In addition to standard-of-care histological evaluation of MASH, including assessment of steatosis, lobular inflammation, ballooning and fibrosis, the company will provide its proprietary AI-based diagnostic test, FibroSight Plus. The solution delivers a fully quantitative assessment of liver fibrosis in MASH liver biopsies.

Dr. Yukti Choudhury, Chief Development Officer at HistoIndex, said, “Partnering with Houston Research Institute represents a significant step forward in our mission to bring quantitative, AI-enabled pathology into MASH clinical care. She added that centralising traditional and AI-enhanced workflows helps streamline turnaround times while maintaining rigorous quality standards.

From a clinical standpoint, the partnership strengthens diagnostic capabilities across HRI’s centres. Dr. Mazen Noureddin, MD, MHS, Director at Houston Research Institute, noted that integrating expert histopathology with quantitative AI-based fibrosis analysis supports more informed clinical decision-making for MASH patients.

The collaboration reflects a shared commitment by HistoIndex and HRI to advance AI-enabled pathology and improve diagnostic accuracy for MASH care across the US.